Erschienen in:
30.10.2018 | Cases with a Message
Cyclophosphamide-induced severe acute hepatitis in a rheumatic disease: case-based review
verfasst von:
Döndü Üsküdar Cansu, Erkin Öztaş, Evrim Yilmaz, Cengiz Korkmaz
Erschienen in:
Rheumatology International
|
Ausgabe 2/2019
Einloggen, um Zugang zu erhalten
Abstract
In rheumatology practice, the risk of hepatotoxicity from medications, including non-steroidal anti-inflammatory drugs, notably, and methotrexate, sulfasalazine, leflunomide, and azathioprine is highly recognized by the rheumatologists. On the other hand, hepatotoxicity is neither a commonly expected nor a well-known side effect of cyclophosphamide (CYC) which is particularly used for vital organ involvements in systemic lupus erythematosus (SLE) and systemic vasculitis. Here we reported a 19-year-old case of SLE who, while on oral CYC treatment of 100 mg/day, was detected to have asymptomatic liver enzyme elevation and then developed acute hepatitis due to intravenously administered high-dose (1 g) CYC for neuro-lupus. Results of liver biopsy indicated drug-related toxicity. We discussed here with the other, although rare, cases available in the literature with an attempt to highlight the risk of hepatotoxicity and acute hepatitis due to CYC.